Royalty Pharma logo 250.jpg
Royalty Pharma Declares Third Quarter 2022 Dividend
July 15, 2022 08:15 ET | RP Management, LLC
NEW YORK, July 15, 2022 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the third quarter of 2022 of $0.19 per Class A...
Royalty Pharma logo 250.jpg
Royalty Pharma to Announce Second Quarter 2022 Financial Results on August 4, 2022
July 14, 2022 08:30 ET | RP Management, LLC
NEW YORK, July 14, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its second quarter 2022 financial results on Thursday, August 4, 2022 before the...
Royalty Pharma logo 250.jpg
Royalty Pharma Agrees to Acquire Royalty Interest in TRELEGY ELLIPTA From Theravance and Innoviva for $1.31 Billion and Potential Milestones of $300 Million
July 13, 2022 16:25 ET | RP Management, LLC
Further diversifies Royalty Pharma’s portfolio with market-leading respiratory therapyExpected to significantly add to long-term Adjusted Cash Receipts growth(1) (non-GAAP) NEW YORK, July 13, 2022 ...
Royalty Pharma logo 250.jpg
Royalty Pharma Acquires Royalty Interest in Gavreto From Blueprint Medicines for up to $340 Million
June 30, 2022 07:31 ET | RP Management, LLC
Attractive, precision oncology therapy with long patent duration added to portfolioBlueprint Medicines to receive $175 million upfront and $165 million in potential milestone payments NEW YORK, June ...
Royalty Pharma logo 250.jpg
Royalty Pharma to Present at the UBS Global Healthcare Conference 2022
May 23, 2022 08:30 ET | RP Management, LLC
NEW YORK, May 23, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it is scheduled to present at the UBS Global Healthcare Conference 2022 on May 24, 2022 at 1:15 p.m....
Royalty Pharma logo 250.jpg
Royalty Pharma Investor Day Highlights Stronger Growth Outlook and the Power of Its Unique Business Model to Drive Value for All Stakeholders
May 17, 2022 07:00 ET | RP Management, LLC
New capital deployment target of $10-12 billion over the next five yearsOutlook for 2020-2025 Adjusted Cash Receipts (1) (non-GAAP) CAGR raised to 11-14%Adjusted Cash Receipts (1) (non-GAAP) expected...
Royalty Pharma logo 250.jpg
Royalty Pharma Reports First Quarter 2022 Results
May 05, 2022 07:00 ET | RP Management, LLC
Net cash provided by operating activities (GAAP) of $460 million; Adjusted Cash Receipts(1) (non-GAAP) of $605 million Announced transactions of up to $450 million in Q1 20222022 guidance reaffirmed:...
Royalty Pharma logo 250.jpg
Royalty Pharma Declares Second Quarter 2022 Dividend
April 18, 2022 08:00 ET | RP Management, LLC
NEW YORK, April 18, 2022 (GLOBE NEWSWIRE) --  The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the second quarter of 2022 of $0.19 per Class A...
Royalty Pharma logo 250.jpg
Royalty Pharma to Announce First Quarter 2022 Financial Results on May 5, 2022
April 13, 2022 08:00 ET | RP Management, LLC
NEW YORK, April 13, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its first quarter 2022 financial results on Thursday, May 5, 2022 before the U.S....
Royalty Pharma logo 250.jpg
Royalty Pharma to Present at Cowen's 42nd Annual Health Care Conference
March 03, 2022 08:30 ET | RP Management, LLC
NEW YORK, March 03, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it is scheduled to participate in a fireside chat at Cowen’s 42nd Annual Health Care Conference on...